{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/","result":{"pageContext":{"chapter":{"id":"c587255a-a47e-57a1-bc4d-967753c38d11","slug":"information-advice-follow-up-referral","fullItemName":"Scenario: Information and advice, follow-up, and referral","depth":2,"htmlHeader":"<!-- begin field 1e603501-9de0-4717-a780-6358faaf4b5c --><h2>Scenario: Information and advice, follow-up, and referral</h2><!-- end field 1e603501-9de0-4717-a780-6358faaf4b5c -->","summary":"Covers the information and advice, follow-up, and referral indicators for people with heart failure.","htmlStringContent":"<!-- begin item 6ab6ef87-d209-4147-a543-f4a7934dd580 --><!-- begin field d415cf91-3b0e-47ec-b1ed-acd900ad56fb --><p>From age 16 years onwards.</p><!-- end field d415cf91-3b0e-47ec-b1ed-acd900ad56fb --><!-- end item 6ab6ef87-d209-4147-a543-f4a7934dd580 -->","topic":{"id":"3a35207f-30ea-5eca-bfcf-dff091a73359","topicId":"fdc42e20-2c4b-45ed-9093-6c2d4bde6e4d","topicName":"Heart failure - chronic","slug":"heart-failure-chronic","lastRevised":"Last revised in January 2017","chapters":[{"id":"77c928c1-46d0-58c1-ba79-6015f89bc48a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f0aa9151-9d10-566e-85ec-6ccefed25f20","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c036596d-f29d-5486-822a-b46af76451d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fd5e8a95-3e97-5ec2-98ae-5a10c2373213","slug":"changes","fullItemName":"Changes"},{"id":"4c4375f1-a348-5b99-b895-f04a15c64791","slug":"update","fullItemName":"Update"}]},{"id":"7472c037-35d4-5fd2-bba6-dfd891ade816","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cde936d1-3945-5bc6-8c22-9106d78cf77c","slug":"goals","fullItemName":"Goals"},{"id":"bfa0b8d3-fac0-500e-a762-f719dc619f1b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5d2cf55e-1ae2-5000-9c94-e9c86d26a824","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c8203a8a-fc22-5378-b33b-34ddf818dea5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4b5e4f72-1a3e-531c-be82-a1919603c934","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c206f1b2-7616-587d-b3bf-b65ba5b5adb4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ab1d2b81-1f2b-55e5-abf0-c14e4ae4a78d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"cb83ac3c-e97e-5cab-acca-5abebc7bd6b1","slug":"definition","fullItemName":"Definition"},{"id":"66c995b7-504c-5510-9e77-1a9b27ee7dca","slug":"causes","fullItemName":"Causes"},{"id":"88dbdf7b-53b7-5952-97b9-2312c0a2ce63","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0b16521-d808-5dfd-89dc-64fc6ae7f6ce","slug":"prognosis","fullItemName":"Prognosis"},{"id":"262fb896-526d-594f-8142-98c291781249","slug":"complications","fullItemName":"Complications"}]},{"id":"72804751-fb0c-5a96-85b5-982feb950f16","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8b798e41-3fbe-5027-9365-da41e1c98e93","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"e6498250-f313-5ea2-a1e8-2d0342823c39","slug":"how-to-manage-suspected","fullItemName":"How to manage suspected"},{"id":"74e553b4-7cb8-52a6-a573-8715f63a2ba8","slug":"how-to-assess","fullItemName":"How to assess"},{"id":"53bf7ae0-a1d0-5fae-9d3b-57cbc6f03bb8","slug":"what-else-could-it-be","fullItemName":"What else could it be"}]},{"id":"38c5edc8-6b4a-5e71-bb70-cf0a09389ae0","fullItemName":"Management","slug":"management","subChapters":[{"id":"97a0eca4-a290-588b-a16a-bc95b93cd893","slug":"confirmed-heart-failure-with-reduced-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with reduced ejection fraction"},{"id":"34ff8094-815a-55b7-9edd-49f3ac636471","slug":"confirmed-heart-failure-with-preserved-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with preserved ejection fraction"},{"id":"28fde475-ef24-59d3-9171-a8d59a3fb149","slug":"end-stage-heart-failure","fullItemName":"Scenario: End-stage heart failure"},{"id":"c587255a-a47e-57a1-bc4d-967753c38d11","slug":"information-advice-follow-up-referral","fullItemName":"Scenario: Information and advice, follow-up, and referral"}]},{"id":"e82d6013-cb43-59d5-9e2e-0af05276fb9d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8fd96acc-3fa6-528b-9351-49db836228b1","slug":"managing-aiiras","fullItemName":"Managing AIIRAs"},{"id":"06c9d276-e5ea-5a0b-9ff4-343f10034763","slug":"managing-ace-inhibitors","fullItemName":"Managing ACE-inhibitors"},{"id":"df53e9a8-07f8-5d37-94cf-78e99d4c8216","slug":"managing-beta-blockers","fullItemName":"Managing beta-blockers"},{"id":"faad170c-d1ee-59ad-9847-f7afdda6d9b9","slug":"managing-diuretics","fullItemName":"Managing diuretics"},{"id":"a3ea6beb-7ee3-586c-9985-47c20d804195","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"7b9c5d56-39f1-53df-b1f9-2dcc5bbb498a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"df3b6e0c-ca5a-59eb-93e6-4b4370389ed2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7a756ff1-7152-5bdd-92ca-7f9e67351dd9","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f5e1707e-f2a9-54e0-92fa-71beb41e38af","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"691681cc-720f-5242-9fb3-3040860027e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7f39ec24-cb87-5fba-ae6b-6fb2d9538859","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4afe2b30-f837-53a3-88df-7b1913a54081","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d4dace55-ef1c-5675-bdbe-180512d549fa","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"38c5edc8-6b4a-5e71-bb70-cf0a09389ae0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"a03cdc85-7dc4-55e6-ad65-04bb5d50d8ff","slug":"information-advice","fullItemName":"Information and Advice","depth":3,"htmlHeader":"<!-- begin field 0126072d-76ef-4560-b4fb-47bba3c086a0 --><h3>What information and advice should I give to a person with confirmed heart failure?</h3><!-- end field 0126072d-76ef-4560-b4fb-47bba3c086a0 -->","summary":null,"htmlStringContent":"<!-- begin item bb100ac8-094f-4711-8f66-def93d4121f4 --><!-- begin field e113ed7f-50be-462e-b7f9-4d888d0885fb --><ul><li><strong>Advise the person about reporting symptoms of worsening heart failure</strong>, including increasing breathlessness, fatigue, ankle or abdominal swelling, and rapid weight gain.<ul><li>Advise them to seek urgent medical advice if symptoms deteriorate.</li></ul></li><li><strong>Consider advising the person to monitor their weight at home to detect fluid retention of worsening heart failure, if practical.</strong><ul><li>Advise the person to check their weight, for example daily, weekly or fortnightly, depending on clinical judgement.<ul><li>Advise the person to weigh themselves at the same time of day (for example after waking and voiding but before dressing or eating).</li><li>Advise what to do if there is a sudden and sustained weight gain (for example more than 2 kg in 3 days). Options include seeking medical advice, increasing the diuretic dose, reducing fluid intake, or a combination of actions.</li><li>The person should understand that deterioration can occur without weight gain.</li></ul></li></ul></li><li><strong>Give advice about:</strong><ul><li><strong>Salt consumption</strong><ul><li>Advise the person to avoid excessive salt intake. Adult daily intake should not exceed 6 g of salt each day (2.5 g of sodium each day).</li><li>Advise people not to replace salt with salt substitutes that are high in potassium, because this may result in hyperkalaemia due to the potassium-sparing effect of angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists (AIIRAs), and aldosterone antagonists.</li><li>Information about salt in the diet can be found on the British Heart Foundation (<a data-hyperlink-id=\"432e55bf-9f0d-4f0e-a135-a93100bbbc8f\" href=\"https://www.bhf.org.uk/heart-health/preventing-heart-disease/healthy-eating/salt\" target=\"\">www.bhf.org.uk</a>) and the British Dietetic Association (<a data-hyperlink-id=\"b166fc5e-cb9b-48d1-9b48-a93100bbbf77\" href=\"https://www.bda.uk.com/foodfacts/salt.pdf\">www.bda.uk.com</a>) websites.</li></ul></li><li><strong>Maintaining fluid balance.</strong><ul><li>People with severe symptomatic heart failure should restrict fluid intake (for example to less than 1.5–2 L a day to relieve symptoms, or consider a weight-based fluid restriction such as 30 mL/kg body weight, or 35 mL/kg body weight for those over 85 kg).</li><li>Restriction of hypotonic fluids may improve hyponatraemia.</li><li>Fluid intake should not be excessively restricted to reduce the risk of dehydration. People should seek medical advice if they feel thirsty, light headed, or dizzy, as this may be a sign of hypotension or hypovolaemia.</li></ul></li><li><strong>What to do if acutely unwell (for example diarrhoea and vomiting).</strong><ul><li>People with stable heart failure taking an ACE-inhibitor, an AIIRA, a diuretic, or an aldosterone antagonist should maintain their fluid intake and stop treatment with these drugs until they recover and are eating and drinking normally. The <a data-hyperlink-id=\"3898dbd0-e39b-4a95-953a-a93100bbc118\" href=\"http://www.scottishpatientsafetyprogramme.scot.nhs.uk/programmes/primary-care/medicine-sick-day-rules-card\">Medicine Sick Day Rules card</a> is available to help raise awareness of potential harms if patients continue to take certain prescribed medicines whilst experiencing a dehydrating illness. </li><li>Be aware of the risk of acute kidney injury (AKI), for example if the person becomes unwell or dehydrated. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/acute-kidney-injury/\">Acute kidney injury</a>.</li><li>If people have severe or uncontrolled heart failure or symptoms of diarrhoea and vomiting persist, they should seek medical advice regarding their medication and checking renal function and electrolytes.</li></ul></li><li><strong>Smoking cessation if relevant.</strong><ul><li>Consider referral to smoking cessation services. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li></ul></li><li><strong>Alcohol consumption.</strong><ul><li>Give advice that people with heart failure should not drink alcohol beyond the recommended levels. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>.</li><li>People with alcohol-related heart failure should be advised to abstain from drinking alcohol.</li></ul></li><li><strong>Physical activity.</strong><ul><li>Regular low-intensity physical activity is recommended for people with <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/background-information/definition/\">stable</a> heart failure.</li><li>For people with New York Heart Association (NYHA) class III or IV heart failure, exercise in water is not recommended.</li><li>Ensure the person has been referred to a <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/confirmed-heart-failure-with-reduced-ejection-fraction/#management\">supervised exercise-based rehabilitation programme</a>.</li></ul></li><li><strong>Nutritional status.</strong><ul><li>If the BMI is under 18.5 kg/m<sup>2</sup>, consider referring the person for dietetic advice.</li><li>If the BMI is over 30 kg/m<sup>2</sup>, give advice on maintaining a healthy weight. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>.</li></ul></li><li><strong>Sexual activity.</strong><ul><li>People with <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/background-information/definition/\">stable</a> heart failure can undertake normal sexual activity that does not provoke undue symptoms.</li><li>For information regarding the use of phosphodiesterase-5 inhibitors for erectile dysfunction in people with heart failure, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/erectile-dysfunction/prescribing-information/\">Prescribing information</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/erectile-dysfunction/\">Erectile dysfunction</a>. If there is uncertainty regarding the appropriateness of drug treatment seek specialist advice.</li></ul></li></ul></li><li><strong>Provide sources of information and support (including helplines, support groups or web-links):</strong><ul><li>NHS A-Z — <a data-hyperlink-id=\"6ff824ae-4e58-45da-a3fa-a93100bbc23c\" href=\"https://www.nhs.uk/conditions/\">www.nhs.uk</a>.</li><li>British Heart Foundation — Living with heart failure, <a data-hyperlink-id=\"c1b8af2b-98d1-44b0-89bc-a93100bbc254\" href=\"https://www.bhf.org.uk/~/media/files/publications/heart-conditions/g275u_an-everyday-guide-to-living-with-heart-failure_0112.pdf\">https://www.bhf.org.uk</a>.</li><li>European Society of Cardiology — Heart failure matters, <a data-hyperlink-id=\"1d1427b5-f4c2-4263-bd84-a93100bbc2bb\" href=\"http://www.heartfailurematters.org/en_GB?gclid=CO-5qI3r08gCFdQaGwodX_MPxA\">http://www.heartfailurematters.org</a>.</li></ul><ul><li>British Society of Heart Failure, <a data-hyperlink-id=\"c253997b-2739-4438-b5aa-a93100bbc440\" href=\"http://www.bsh.org.uk/patients/basics/\">http://www.bsh.org.uk</a>.</li></ul></li></ul><!-- end field e113ed7f-50be-462e-b7f9-4d888d0885fb --><!-- end item bb100ac8-094f-4711-8f66-def93d4121f4 -->","subChapters":[{"id":"359b7aef-bf22-5c1b-a598-863241119e82","slug":"driving-advice","fullItemName":"Driving advice","depth":4,"htmlHeader":"<!-- begin field cc09bb2d-3ccd-45f4-9d71-a75e00c2de66 --><h4>What advice should I give about driving and chronic heart failure?</h4><!-- end field cc09bb2d-3ccd-45f4-9d71-a75e00c2de66 -->","summary":null,"htmlStringContent":"<!-- begin item 664057f4-e8da-4fc0-a039-a75e00c2df27 --><!-- begin field 0e00f41f-4ae6-49ed-ae42-a75e00c2de66 --><ul><li><strong>Advise the person that:</strong><ul><li>It is the person's responsibility to inform the Driver and Vehicle Licensing Agency (DVLA) of any condition that may affect their ability to drive, and people should check with their insurer that they are still covered to drive.</li></ul></li><li>The latest information from the DVLA regarding medical fitness to drive can be obtained in the DVLA document <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/351444/aagv1.pdf\" data-hyperlink-id=\"4a21fa2e-c518-4e77-8f1b-a93100bb891e\">Medical Standards of Fitness to Drive</a>.<ul><li><strong>For group 1 entitlement (cars, motorcycles):</strong> driving may continue, provided there are no symptoms that may distract the driver's attention. The DVLA need not be notified.</li><li><strong>For group 2 entitlement (lorries and buses):</strong> the person is disqualified from driving if symptomatic. Re-licensing may be permitted, provided that the left ventricular ejection fraction is at least 40% and there is no disqualifying condition. Exercise or other functional testing may be required, depending on the likely cause of heart failure.</li></ul></li><li>There are also specific regulations not described here for possible associated underlying conditions such as angina, arrhythmias, valve disease, and cardiomyopathies, for symptoms such as syncope, ECG abnormalities such as left bundle branch block, and for treatments such as implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy. For full and current information, see the DVLA document <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/351444/aagv1.pdf\" data-hyperlink-id=\"0d497cfb-74b7-4b89-bddf-a93100bb89db\">Medical Standards of Fitness to Drive</a>.</li></ul><!-- end field 0e00f41f-4ae6-49ed-ae42-a75e00c2de66 --><!-- end item 664057f4-e8da-4fc0-a039-a75e00c2df27 -->","subChapters":[]},{"id":"f6343310-dde2-5183-b172-4452db2350da","slug":"travel-advice","fullItemName":"Travel advice","depth":4,"htmlHeader":"<!-- begin field 95f32481-468c-4c2a-9b1a-a75e00c2fe80 --><h4>What information should I give about travel?</h4><!-- end field 95f32481-468c-4c2a-9b1a-a75e00c2fe80 -->","summary":null,"htmlStringContent":"<!-- begin item 9f58f09a-8586-4724-9aca-a75e00c2fed9 --><!-- begin field ff61b3ea-e471-4c84-a1a9-a75e00c2fe80 --><ul><li><strong>Give general advice:</strong><ul><li>To continue regular medication and to carry extra medication as a precaution during travel.</li><li>For aeroplane travel, advise people to carry their medication in their hand luggage.</li><li>To carry a written record of medical history and current drug treatment.</li><li>To monitor fluid intake and risk of dehydration, for example during flights and in hot climates. For further information regarding the management of fluids, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#information-advice\">Self-care advice</a>.</li><li>To be aware of possible adverse reactions to sun exposure with certain drugs (for example amiodarone).</li></ul></li><li>Information from the Civil Aviation Authority regarding fitness for flying can be obtained in the document <a href=\"http://www.caa.co.uk/Passengers/Before-you-fly/Am-I-fit-to-fly/Guidance-for-health-professionals/Assessing-fitness-to-fly/\" data-hyperlink-id=\"22e50e30-414a-404a-9afc-a93100ae1228\">Assessing fitness to fly: Guidelines for health professionals</a> (<a href=\"http://www.caa.co.uk/\" data-hyperlink-id=\"ab396238-9526-4db0-ad25-a93100ae1235\">www.caa.co.uk</a>). This includes advice regarding:<ul><li>Contraindications to flying.</li><li>Travel with pacemakers or implantable cardioverter defibrillators (ICDs).</li><li>Circumstances where the airline should be informed of the person's condition (so that special consideration can be given to issues such as wheelchair provision, preferential aeroplane access, or access to in-flight oxygen).</li></ul></li></ul><!-- end field ff61b3ea-e471-4c84-a1a9-a75e00c2fe80 --><!-- end item 9f58f09a-8586-4724-9aca-a75e00c2fed9 -->","subChapters":[]},{"id":"95ba7aaf-0c10-527f-af57-e43c6fe33138","slug":"basis-for-recommendation-b59","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 87952ea9-0548-44d0-a9bf-a75e00c2010f --><h4>Basis for recommendation</h4><!-- end field 87952ea9-0548-44d0-a9bf-a75e00c2010f -->","summary":null,"htmlStringContent":"<!-- begin item b5911350-5850-47f7-a807-a75e00c2019e --><!-- begin field d46fc7f3-2f1b-4945-8636-a75e00c2010f --><p>These recommendations are based on guidance issued by the Scottish Intercollegiate Guidelines Network (SIGN) <em>Management of chronic heart failure: a national clinical guideline</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>], the National Institute for Health and Clinical Excellence (NICE) <em>Chronic heart failure in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>], the European Society of Cardiology <em>Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>], and the <em>Guideline for the management of heart failure</em> from the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Yancy et al, 2013</a>].</p><h5>Reporting worsening symptoms of heart failure</h5><ul><li>This recommendation is based on information in the European Society of Cardiology guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>].</li></ul><h5>Home weight monitoring</h5><ul><li>Rapid weight gain in people with heart failure may be the result of fluid retention, and worsening heart failure may be detected early if weight is measured regularly. The recommendation regarding self-monitoring of weight is based on information in the European Society of Cardiology guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>], and expert opinion in a narrative review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Williams and Oakeshott, 2014b</a>], although evidence from one small study (n = 77) indicated that increases in body weight were not always associated with a deterioration of symptoms of heart failure and fluid retention [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Lewin et al, 2005</a>].</li></ul><h5>Advice on salt consumption</h5><ul><li>The recommendations to avoid excess salt consumption and not to replace salt with salt substitutes high in potassium are based on information in the SIGN guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>].</li></ul><h5>Advice on maintaining fluid balance</h5><ul><li>The recommendation to restrict fluid intake in people with severe symptoms of heart failure is based on information in the European Society of Cardiology guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>].</li><li>The recommendation regarding when to seek specialist advice is pragmatic and based on what CKS considers to be good medical practice.</li></ul><h5>Advice on acute illness</h5><ul><li>The recommendation to temporarily stop treatment with an angiotensin-converting enzyme (ACE) inhibitor, angiotensin-II receptor antagonist (AIIRA), diuretic, or spironolactone is based on concern that continued treatment may increase the risk of acute kidney injury in a retrospective cohort survey [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Stirling et al, 2003</a>], the NICE guideline <em>Acute kidney injury: prevention, detection and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2013</a>], and the expert opinion of previous external reviewers of this CKS topic. Stopping treatment for a short time is thought to reduce the risk of dehydration, hypotension, and acute kidney injury, and should not cause a sudden deterioration of symptoms in people with stable heart failure.</li><li>Information on the availability of the Medicines Sick Day rules card is based on the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of chronic heart failure </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>].</li></ul><h5>Advice on smoking cessation</h5><ul><li>This recommendation is based on expert opinion in the guidelines from the Scottish Intercollegiate Guidelines Network (SIGN) <em>Management of chronic heart failure</em><em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>] and NICE [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>].</li></ul><h5>Advice on alcohol consumption</h5><ul><li>The recommendation that people with heart failure should drink alcohol within recommended levels is based on expert opinion in the SIGN guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>]. Specific limits of alcohol consumption (2 units per day for men and 1 unit per day for women) are recommended in the guidelines from the European Society of Cardiology <em>Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>]. The NICE guideline recommends a discussion of alcohol consumption and tailoring advice appropriately to the clinical circumstances [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>].</li><li>The recommendation that people with alcohol-related heart failure should be advised to stop drinking alcohol is based on information in the SIGN [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>] and NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>].</li></ul><h5>Advice on physical activity</h5><ul><li>The recommendation on regular low-intensity physical activity in people with stable heart failure is based on the SIGN guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>].</li><li>The recommendation to avoid exercise in water in people with NYHA class III and IV heart failure is because immersion in water creates enhanced preload which has been associated with abnormal cardiac responses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>].</li></ul><h5>Advice on nutritional status</h5><ul><li>The recommendation to advise people to eat healthily and to maintain a healthy weight is based on information in the European Society of Cardiology <em>Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>], and the NICE guideline recommends assessing nutritional status at clinical review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>]. The threshold for dietetic advice is pragmatic and based on what CKS considers to be good medical practice. The recommendation regarding management of obesity is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Williams and Oakeshott, 2014b</a>].</li></ul><h5>Advice on sexual activity</h5><ul><li>The recommendation that people with stable symptoms of heart failure can undertake normal sexual activity that does not provoke undue symptoms is based on information in the European Society of Cardiology guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>].</li></ul><h5>Providing sources of information and support</h5><ul><li>Offering personalized information, education, support and opportunities for discussion throughout their care to people with heart failure to help them understand their condition and be involved in their management, if they wish, is a National Institute for Health and Care Excellence (NICE) quality standard [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2011</a>].</li><li>The European Society of Cardiology guideline recommends that people should be provided with information to help understand the cause of heart failure, why symptoms occur, understand important prognostic factors, and understand the indications, dosing, and effects of each drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>].</li></ul><h5>Advice on driving</h5><ul><li>The recommendations on driving regulations is based on information in the Driver and Vehicle Licensing Agency (DVLA) document <span class=\"Italic\"><em>At a glance guide to the current medical standards of fitness to drive</em></span> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">DVLA, 2015</a>].</li></ul><h5>Advice on travel</h5><ul><li>The general travel information and advice is based on recommendations in the European Society of Cardiology <em>Guidelines for the diagnosis and treatment of acute and chronic heart failure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>].</em></li></ul><h5>Advice on flying</h5><ul><li>The recommendations on flying are based on information in the Civil Aviation Authority document <em>Assessing fitness to fly: Guidelines for health professionals</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Civil Aviation Authority, 2015</a>].</li></ul><!-- end field d46fc7f3-2f1b-4945-8636-a75e00c2010f --><!-- end item b5911350-5850-47f7-a807-a75e00c2019e -->","subChapters":[]}]},{"id":"912b3672-27fa-58b3-aa16-992a3d648d75","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field cf22c402-c122-4548-ad99-555203c1e58e --><h3>When should I refer a person with heart failure?</h3><!-- end field cf22c402-c122-4548-ad99-555203c1e58e -->","summary":null,"htmlStringContent":"<!-- begin item 158cd7c5-6ae0-4c1e-8c0a-40227f8abdab --><!-- begin field 0bb89bac-534c-4b21-a7f6-d3ff1ee9111f --><ul><li><strong>Refer to a specialist multidisciplinary heart failure team (where available) or cardiology service for <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#specialist-treatment\">specialist treatment</a> if a person has:</strong><ul><li>Severe heart failure (New York Heart Association [NYHA] class IV).</li><li>Heart failure that does not respond to treatment in primary care or can no longer be managed in the home setting.</li><li>Heart failure resulting from valvular heart disease.</li><li>Left ventricular ejection fraction of 35% or less.</li></ul></li><li><strong>Consider referral for a person with heart failure and a comorbidity</strong> such as chronic kidney disease or chronic obstructive pulmonary disease.</li><li><strong>Refer women with heart failure and reduced ejection fraction (HF-REF) who are planning a pregnancy for specialist pre-conceptual advice, and refer women who are pregnant for specialist management.</strong><ul><li>Women who wish to conceive should be advised to continue contraception until they have seen an obstetrician and cardiologist for pre-conceptual advice.</li></ul></li></ul><!-- end field 0bb89bac-534c-4b21-a7f6-d3ff1ee9111f --><!-- end item 158cd7c5-6ae0-4c1e-8c0a-40227f8abdab -->","subChapters":[{"id":"ed08b306-a71e-527f-96cd-826d77568e88","slug":"specialist-treatment","fullItemName":"Specialist treatment","depth":4,"htmlHeader":"<!-- begin field 19a7ebc9-e700-47be-9f53-a75e00bea244 --><h4>Specialist treatment</h4><!-- end field 19a7ebc9-e700-47be-9f53-a75e00bea244 -->","summary":null,"htmlStringContent":"<!-- begin item 3d24d2d0-a92e-4e51-855e-a75e00bea131 --><!-- begin field bc4154b3-94c4-46bd-968b-a75e00bea244 --><ul><li><strong>The following specialist treatments may be initiated after specialist assessment:</strong></li><li><strong>Drug treatment</strong><ul><li>Combination of loop and thiazide diuretic.</li><li>Aldosterone antagonist (spironolactone or eplerenone).</li><li>Sacubitril valsartan.</li><li>Hydralazine in combination with a nitrate (especially if the person is of Afro-Caribbean origin).</li><li>Digoxin.</li><li>Ivabradine (slows the heart rate in sinus rhythm).</li><li>Anticoagulation — may be indicated for people with heart failure who are in sinus rhythm and have a history of thromboembolism, left ventricular aneurysm, or intracardiac thrombus.</li><li>Intravenous iron. </li></ul></li><li><strong>Surgical intervention</strong><ul><li>Cardiac resynchronisation therapy.</li><li>Insertion of an implantable cardioverter defibrillator (ICD).</li><li>Coronary revascularization.</li><li>Cardiac transplantation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">National Clinical Guideline Centre for Acute and Chronic Conditions, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">McKelvie et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>]</p><!-- end field bc4154b3-94c4-46bd-968b-a75e00bea244 --><!-- end item 3d24d2d0-a92e-4e51-855e-a75e00bea131 -->","subChapters":[]},{"id":"d497098e-e867-5159-84b2-321761491059","slug":"basis-for-recommendation-94d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 992d5ee2-2a22-4c2b-a784-5853e9e9e100 --><h4>Basis for recommendation</h4><!-- end field 992d5ee2-2a22-4c2b-a784-5853e9e9e100 -->","summary":null,"htmlStringContent":"<!-- begin item 94db920e-0177-44ea-8e1f-50d81a26d8c6 --><!-- begin field 2f9c23bc-703f-4872-881e-eac56d4334c0 --><h5>Indications for referral to a specialist heart failure team</h5><ul><li>The recommendations for referral of people with severe heart failure, heart failure which does not respond to treatment in primary care or the home setting is based on information in the National Institute for Health and Clinical Excellence (NICE) guideline <em>Chronic heart failure in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>].</li><li>The recommendation to refer people with heart failure resulting from valvular heart disease is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Al-Mohammad et al, 2010</a>].</li><li>The recommendation to refer people who have a left ventricular ejection fraction of 35% or less is based on information in a NICE technology appraisal that these people may be suitable for specialist treatments including implantable cardioverter defibrillators (ICDs), cardiac resynchronisation therapy (CRT) with defibrillator (CRT-D) or pacing (CRT-P) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2014</a>].</li></ul><h5>Considering referral for people with comorbidities</h5><ul><li>This recommendation is based on expert opinion in a review article which recommends optimizing the management of comorbidities [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Williams and Oakeshott, 2014b</a>], and is pragmatic and based on what CKS considers to be good medical practice.</li></ul><h5>Referral of women planning a pregnancy and women who are pregnant</h5><ul><li>These recommendations are based on information in the guidelines from the European Society of Cardiology <em>Guidelines on the management of cardiovascular diseases during pregnancy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2011</a>], the Royal College of Obstetricians and Gynaecologists <em>Cardiac disease and pregnancy </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">RCOG, 2011</a>], and the Faculty of Sexual and Reproductive Healthcare clinical guidance <em>Contraceptive choices for women with cardiac disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">FSRH, 2014b</a>].</li></ul><!-- end field 2f9c23bc-703f-4872-881e-eac56d4334c0 --><!-- end item 94db920e-0177-44ea-8e1f-50d81a26d8c6 -->","subChapters":[]}]},{"id":"8bbaa324-efb1-5663-a130-fcec931801b5","slug":"follow-up","fullItemName":"Follow-up","depth":3,"htmlHeader":"<!-- begin field 02cb2759-a20f-4fdf-b67f-e5bb2c7e3971 --><h3>How should I follow up a person with heart failure?</h3><!-- end field 02cb2759-a20f-4fdf-b67f-e5bb2c7e3971 -->","summary":null,"htmlStringContent":"<!-- begin item e1ba20e8-2d56-4fae-85ce-7f05479db960 --><!-- begin field 08acbeba-24dc-4257-955b-4ba5969c58a4 --><ul><li><strong>All people with heart failure require regular follow up and monitoring.</strong><ul><li>Heart failure care should be delivered by a dedicated multidisciplinary team which may include a dedicated heart failure nurse, as well as a pharmacist to provide advice to people about drugs and compliance, and feedback to clinicians about optimising pharmacological interventions. </li><li>The frequency of follow up needs to be individualized to the severity and stability of symptoms, treatment, and comorbidities.<ul><li>The follow up interval should be short (days to 2 weeks) if the person's clinical condition or drugs have changed, and at least every 6 months if the person's condition is stable.</li></ul></li><li>Consider monitoring the N-terminal pro-BNP (NT-pro-BNP) levels (depending on local availability) in people less than 75 years of age to guide optimum drug treatment, especially for those with a higher baseline NT-prob-BNP level (greater than 2114 pg/mL).</li><li>Ensure that sources of <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#information-advice\">information and advice</a> have been given to the person and their carers/family and provide information on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#information-advice\">self-care advice</a>.</li></ul></li><li><strong>Assess and monitor symptoms and signs of heart failure:</strong><ul><li><strong>Ask about palpitations, shortness of breath, presence of oedema, syncopal and presyncopal symptoms.</strong><ul><li>If the person has syncope or presyncope (unless clearly due to postural hypotension), refer to a cardiologist as this may be due to ventricular tachycardia, particularly in people who have a reduced ejection fraction (HF-REF).</li></ul></li><li><strong>Check the person's pulse rate and rhythm and examine the heart:</strong><ul><li>If an arrhythmia is suspected, arrange a 12-lead ECG or 24-hour ECG monitoring. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palpitations/\">Palpitations</a>.</li><li>If symptoms have deteriorated and the pulse is regular, consider arranging an ECG to assess for the presence of an atrial tachycardia.</li></ul></li><li><strong>Assess fluid status by checking for:</strong><ul><li>Changes in <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#information-advice\">body weight</a>.</li><li>Oedema (abdomen, sacrum, genitalia, and ankles).</li><li>Raised jugular venous pressure.</li><li>Fine lung crepitations.ood </li><li>Hepatomegaly (liver engorgement).</li><li>Postural drop in blood pressure (a postural decrease of more than 20 mmHg suggests hypovolaemia).</li></ul></li></ul></li><li><strong>Assess the person's functional capacity </strong>— ask about ability to perform everyday activities using the New York Heart Association (NYHA) classification.</li><li><strong>Assess cognitive status and any psychosocial needs</strong>, including anxiety and depression. For further information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>.</li><li><strong>Provide a <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#information-advice\">self-management plan</a>.</strong></li><li><strong>Assess the person's <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#information-advice\">nutritional status</a>.</strong></li><li><strong>Review the person's medications</strong> (and ask about possible adverse effects) including over-the-counter preparations.</li><li><strong>Ensure the person has been offered a <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/confirmed-heart-failure-with-reduced-ejection-fraction/#management\">supervised group exercise-based heart failure rehabilitation programme</a>.</strong></li><li><strong>Ensure <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/confirmed-heart-failure-with-reduced-ejection-fraction/#management\">immunizations</a> are up-to-date.</strong></li><li><strong>Monitor the serum urea, electrolytes, and estimated glomerular filtration rate (eGFR) every 6 months.</strong></li><li><strong>Consider if <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#referral\">referral</a> is indicated.</strong></li><li><strong>Provide women of child-bearing age with advice about <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/confirmed-heart-failure-with-reduced-ejection-fraction/#management\">contraception</a> and pregnancy.</strong></li></ul><!-- end field 08acbeba-24dc-4257-955b-4ba5969c58a4 --><!-- end item e1ba20e8-2d56-4fae-85ce-7f05479db960 -->","subChapters":[{"id":"1ed90937-2447-5273-abf6-b5554d16f85a","slug":"basis-for-recommendation-04f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 524b5e01-bf7b-47fb-8817-4f853fd75a4c --><h4>Basis for recommendation</h4><!-- end field 524b5e01-bf7b-47fb-8817-4f853fd75a4c -->","summary":null,"htmlStringContent":"<!-- begin item 04f3c4e3-26cb-41fa-9b3e-b7dfdc5ff8fd --><!-- begin field a856a0f6-3dc3-475f-9957-1834bbea9506 --><h5>Follow-up and monitoring recommendations</h5><ul><li>These recommendations are based on expert opinion in the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of chronic heart failure</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>], and the National Institute for Health and Clinical Excellence (NICE) guideline <em>Chronic heart failure in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>].</li><li>The recommendation that people with stable chronic heart failure receive a clinical assessment at least every 6 months including a medication review and measurement of renal function is a NICE chronic heart failure quality standard [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2011</a>].</li><li>The recommendations to include pharmacists in the multidisciplinary team, and to consider monitoring the N-terminal pro-BNP (NT-pro-BNP) levels in people less than 75 years of age to guide optimum drug treatment are based on the SIGN guideline <em>Management of chronic heart failure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>].</em></li></ul><h5>Assessing and monitoring symptoms and signs</h5><ul><li>It is important to regularly and routinely assess people with heart failure as they may have a treatable arrhythmia (especially atrial fibrillation), which may present at any time before, at, or after the initial presentation with heart failure. Assessment of the pulse is recommended in the NICE guideline <em>Chronic heart failure: national clinical guideline for diagnosis and management in primary and secondary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>].</li><li>The recommendation to arrange an ECG if symptoms deteriorate and the pulse is regular is pragmatic and based on what CKS considers to be good medical practice, as atrial tachycardia can be regular and may be missed on clinical examination.</li><li>The recommendation to assess fluid status to review response to treatment and guide further management is based on information in the NICE guideline <em>Chronic heart failure in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>] </li></ul><h5>Assessing functional capacity</h5><ul><li>A clinical assessment of functional capacity at follow-up is based on expert opinion in the NICE guideline <em>Chronic heart failure in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>].</li></ul><h5>Assessing cognitive status and any psychosocial needs</h5><ul><li>The NICE guideline <em>Chronic heart failure in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>]<em> </em>recommends monitoring cognitive status and that a diagnosis of depression should be considered in all people with heart failure. Where depression is likely to have been precipitated by heart failure symptoms, the person should be reassessed once their physical symptoms have been stabilised following treatment for heart failure.</li></ul><h5>Reviewing medication</h5><ul><li>The NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>] recommends asking about self-medication due to the potential interaction of prescribed medication with over-the-counter treatment for depression such as St John's wort, and recommends a review of all medication and adverse effects.</li></ul><h5>Assessing the person's nutritional status</h5><ul><li>This recommendation is based on information in the NICE guideline <em>Chronic heart failure in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>].</li></ul><h5>Offering a group exercise-based rehabilitation programme</h5><ul><li>Information to ensure people have been offered a supervised group exercise-based heart failure rehabilitation programme is based on information in the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>].</li></ul><h5>Ensuring immunizations are up-to-date</h5><ul><li>The recommendations on immunizations are based on the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>].</li></ul><h5>Monitoring serum urea, electrolytes, and estimated glomerular filtration rate (eGFR) regularly</h5><ul><li>The recommendation to monitor serum urea, electrolytes, creatinine and eGFR every 6 months is based on information in the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>] and is a NICE quality standard [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2011</a>].</li></ul><h5>Considering referral</h5><ul><li>The recommendation to consider whether referral is indicated is pragmatic and based on what CKS considers to be good medical practice.</li></ul><h5>Advice for women of child-bearing age</h5><ul><li>These recommendations are based on information in the European Society of Cardiology <em>Guidelines on the management of cardiovascular diseases during pregnancy </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2011</a>], the Royal College of Obstetricians and Gynaecologists <em>Cardiac disease and pregnancy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">RCOG, 2011</a>], and the Faculty of Sexual and Reproductive Healthcare clinical guidance <em>Contraceptive choices for women with cardiac disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">FSRH, 2014b</a>].</li></ul><!-- end field a856a0f6-3dc3-475f-9957-1834bbea9506 --><!-- end item 04f3c4e3-26cb-41fa-9b3e-b7dfdc5ff8fd -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}